uu.seUppsala University Publications
Change search
Link to record
Permanent link

Direct link
BETA
Yi-Ting, Lin
Publications (5 of 5) Show all publications
Wu, P.-H., Yi-Ting, L., Wu, P.-Y., Huang, J.-C., Chen, S.-C., Chang, J.-M. & Chen, H.-C. (2019). A Low Ankle-Brachial Index and High Brachial-Ankle Pulse Wave Velocity Are Associated with Poor Cognitive Function in Patients Undergoing Hemodialysis. Disease Markers, 2019, Article ID 9421352.
Open this publication in new window or tab >>A Low Ankle-Brachial Index and High Brachial-Ankle Pulse Wave Velocity Are Associated with Poor Cognitive Function in Patients Undergoing Hemodialysis
Show others...
2019 (English)In: Disease Markers, ISSN 0278-0240, E-ISSN 1875-8630, Vol. 2019, article id 9421352Article in journal (Refereed) Published
Abstract [en]

Patients with end-stage renal disease (ESRD) have an increased risk of both impaired cognitive function and peripheral artery disease (PAD) than the general population. The association between PAD and dementia is recognized, but there are limited studies in patients with ESRD. The aim of this study was to evaluate the relationship between ankle-brachial index (ABI) and brachial-ankle pulse wave velocity (baPWV) and cognitive impairment in patients receiving hemodialysis (HD). We enrolled 136 prevalent HD patients (mean age 59.3 +/- 10.5 years, 55.9% male). Cognitive performance was measured using the Montreal Cognitive Assessment (MoCA) and Cognitive Abilities Screening Instrument (CASI) by trained psychiatrists. Associations between the cognitive function and ABI and baPWV were assessed using multiple linear regression analysis. Compared with HD patients with ABI >= 0.9, patients with ABI<0.9 had lower MoCA score (p=0.027) and lower CASI score but did not achieve significant level (p=0.056). In the multivariate stepwise linear regression analysis, ABI (per 0.1) was independently positively associated with the MoCA score (beta coefficient=0.62, p=0.011) and the CASI score (beta coefficient=1.43, p=0.026). There is a negative association between baPWV (per 100cm/s) and CASI (beta coefficient=-0.70, p=0.009). In conclusion, a low ABI or high baPWV was associated with a lower cognitive function in HD patients.

National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-394270 (URN)10.1155/2019/9421352 (DOI)000484834000001 ()
Available from: 2019-10-09 Created: 2019-10-09 Last updated: 2019-10-09Bibliographically approved
Yi-Ting, L., Chou, M.-C., Wu, S.-J. & Yang, Y.-H. (2019). Galantamine plasma concentration and cognitive response in Alzheimer's disease. PeerJ, 7, Article ID e6887.
Open this publication in new window or tab >>Galantamine plasma concentration and cognitive response in Alzheimer's disease
2019 (English)In: PeerJ, ISSN 2167-8359, E-ISSN 2167-8359, Vol. 7, article id e6887Article in journal (Refereed) Published
Abstract [en]

Background

Galantamine has been approved for the treatment of Alzheimer's disease (AD). However, there are few studies which have reported the association between cognitive responses and galantamine plasma concentration. The aim of this study was to determine the correlation between galantamine plasma concentration and the subsequent cognitive response following treatment in AD patients.

Methods

ADsufferers who continuously took 8 mg/d galantamine for at least 6 months without previous exposure to other kinds of AChEI such as donepezil, rivastigmine, or memantine were included in this cohort study. The assessments included the Mini Mental Status Examination (MMSE), Clinical Dementia Rating Scale (CDR) and the Cognitive Assessment Screening Instrument (CASI). Each subdomain of the CASI assessment was conducted at baseline and after 6 months of galantamine. The plasma concentrations of galantamine were measured by capillary electrophoresis after 6 months of the treatment. Logistic regression was performed to adjust for age, gender, apolipoprotein E epsilon 4 genotype status, and baseline score to investigate the association between galantamine plasma concentrations and the cognitive response.

Results

The total sample consisted of 33 clinically diagnosed AD patients taking galantamine 8 mg/d for 6 months. There was no linear correlation between galantamine concentration and cognitive response in patients. However, 22 patients were responsive to the treatment in the long-term memory domain. In CASI subset domain, concentration improved during the 6 months follow up.

Conclusions

In the limited samples study, galantamine mostly benefitted the cognitive domain of long-term memory. The benefits were not related to the galantamine plasma concentration. Objective intra-individual evaluation of therapeutic response should be encouraged.

Keywords
Alzheimer's disease, Galantamine, Cognitive response, Cholinesterase inhibitors, MMSE
National Category
Psychiatry Neurology
Identifiers
urn:nbn:se:uu:diva-383504 (URN)10.7717/peerj.6887 (DOI)000466458700007 ()
Available from: 2019-05-17 Created: 2019-05-17 Last updated: 2019-05-17Bibliographically approved
Yi-Ting, L., Wu, P.-H., Lee, H.-H., Mubanga, M., Chen, C.-S., Kuo, M.-C., . . . Hwang, S.-J. (2019). Indole-3 acetic acid increased risk of impaired cognitive function in patients receiving hemodialysis. Neurotoxicology, 73, 85-91
Open this publication in new window or tab >>Indole-3 acetic acid increased risk of impaired cognitive function in patients receiving hemodialysis
Show others...
2019 (English)In: Neurotoxicology, ISSN 0161-813X, E-ISSN 1872-9711, Vol. 73, p. 85-91Article in journal (Refereed) Published
Abstract [en]

Patients receiving hemodialysis (HD) have a higher risk of cognitive impairment and dementia than the general population. The accumulation of uremic toxins in the brain causes uremic encephalopathy, however, limited data exists to elucidate the effect of protein-bound uremic toxins on cognitive function. Here we investigate the effect of indole-3 acetic acid (IAA) and hippuric acid (HA), two different protein-bound uremic toxins from amino acid derivatives, on cognitive function by Silico and in a clinical study. Prevalent HD patients were enrolled in two independent hospitals. Serum IAA and HA were measured using mass spectrometry. Cognitive performance was measured using Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and Cognitive Abilities Screening Instrument (CASI) by trained psychologists. Using silico data to predict the effect of blood-brain barrier penetration was performed. The silico data demonstrated that IAA and HA had positive blood-brain barrier penetration ability. Amongst the 230 HD patients, serum IAA was associated with poor MMSE score (beta = -0.90, 95% CI -1.61 to -0.19) and poor CASI score (beta = -3.29, 95% CI -5.69 to -0.88) in stepwise multiple linear regression analysis. In logistic regression model, Serum IAA was also associated with cognitive impairment based on MMSE definition (OR, 1.96, 95% CI 1.10, 3.5) and CASI definition (OR, 2.09, 95% CI 1.21, 3.61). There was no correlation between Serum HA levels and cognitive function status. In conclusion, IAA, not HA, was associated with cognitive impairment in HD patients. Further large scale and prospective studies are needed to confirm our findings.

Place, publisher, year, edition, pages
ELSEVIER, 2019
Keywords
Indole-3 acetic acid, Cognitive function, Dementia, Chronic kidney disease, Hemodialysis
National Category
Neurology
Identifiers
urn:nbn:se:uu:diva-392874 (URN)10.1016/j.neuro.2019.02.019 (DOI)000477692600009 ()30826344 (PubMedID)
Available from: 2019-09-26 Created: 2019-09-26 Last updated: 2019-09-26Bibliographically approved
Yi-Ting, L., Fall, T., Hammar, U., Gustafsson, S., Ingelsson, E., Ärnlöv, J., . . . Sundström, J. (2019). Proteomic Analysis of Longitudinal Changes in Blood Pressure. JOURNAL OF CLINICAL MEDICINE, 8(10), Article ID 1585.
Open this publication in new window or tab >>Proteomic Analysis of Longitudinal Changes in Blood Pressure
Show others...
2019 (English)In: JOURNAL OF CLINICAL MEDICINE, ISSN 2077-0383, Vol. 8, no 10, article id 1585Article in journal (Refereed) Published
Abstract [en]

Hypertension is the leading risk factor for premature death worldwide. The identification of modifiable causes of hypertension remains an imperative task. We aimed to investigate associations between 79 proteins implicated in cardiovascular disease and longitudinal blood pressure (BP) changes in three Swedish prospective cohorts. In a discovery phase, we investigated associations between baseline circulating protein levels assessed with a proximity extension assay and BP stage progression at follow-up 5 years later among persons without BP-lowering drugs at baseline in two independent community-based cohorts from the Prospective Investigation of the Vasculature in Uppsala Seniors study (PIVUS) and the Uppsala Longitudinal Study of Adult Men (ULSAM). We used an independent cohort, the Malmo Diet and Cancer Study (MDC), for replication. The primary outcome of BP stage progression was defined as per the 2017 AHA/ACC (American Heart Association/American College of Cardiology) Guideline BP categories. We also investigated associations of protein levels with changes in BP on a continuous scale, and meta-analyzed all three cohorts. Levels of renin were associated with BP stage progression with a 5% false discovery rate (FDR) in the ULSAM (n = 238) and PIVUS (n = 566) cohorts, but we could not replicate this association in the MDC cohort (n = 2659). The association in the discovery cohorts was modest, with an odds ratio for BP stage progression over 5 years of 1.33 (95% confidence interval 1.14 to 1.56) per standard deviation of baseline renin. In conclusion, we could not find any novel robust associations with longitudinal BP increase in a proximity extension assay-based proteomics investigation in three cohorts.

Place, publisher, year, edition, pages
MDPI, 2019
Keywords
proteomics, blood pressure, hypertension, prospective cohort
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:uu:diva-400097 (URN)10.3390/jcm8101585 (DOI)000498398500083 ()31581667 (PubMedID)
Funder
Swedish Heart Lung Foundation, 20041151
Available from: 2020-01-07 Created: 2020-01-07 Last updated: 2020-01-07Bibliographically approved
Yi-Ting, L., Fall, T., Gustafsson, S., Ingelsson, E., Arnlov, J., Lind, L., . . . Sundström, J. (2018). Use of Proteomics to Investigate Blood Pressure Progress in the Elderly. Paper presented at 27th Scientific Meeting of the International-Society-of-Hypertension, SEP 20-23, 2018, Beijing, PEOPLES R CHINA. Journal of Hypertension, 36, E115-E115
Open this publication in new window or tab >>Use of Proteomics to Investigate Blood Pressure Progress in the Elderly
Show others...
2018 (English)In: Journal of Hypertension, ISSN 0263-6352, E-ISSN 1473-5598, Vol. 36, p. E115-E115Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
Lippincott Williams & Wilkins, 2018
Keywords
proteomics, blood pressure, hypertension, renin
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:uu:diva-376317 (URN)10.1097/01.hjh.0000548461.65063.9a (DOI)000455594802066 ()
Conference
27th Scientific Meeting of the International-Society-of-Hypertension, SEP 20-23, 2018, Beijing, PEOPLES R CHINA
Available from: 2019-02-04 Created: 2019-02-04 Last updated: 2019-02-04Bibliographically approved
Organisations

Search in DiVA

Show all publications